Meeting
2023 ASCO Genitourinary Cancers Symposium
Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) that progressed after prior checkpoint inhibitor (CPI) therapy.
Authors
Daniel P. Petrylak
Yale School of Medicine, New Haven, CT
Daniel P. Petrylak , Scott T. Tagawa , Rohit K. Jain , Manojkumar Bupathi , Arjun V. Balar , Arash Rezazadeh , Saby George , Phillip Lee Palmbos , Luke T. Nordquist , Nancy B. Davis , Chethan Ramamurthy , Cora N. Sternberg , Yohann Loriot , Neeraj Agarwal , Chandler H. Park , Julia Tonelli , Morganna Vance , Huafeng Zhou , Petros Grivas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03547973
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 520)
DOI
10.1200/JCO.2023.41.6_suppl.520
Abstract #
520
Poster Bd #
C6
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Updated outcomes in TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI).
First Author: Scott T. Tagawa
Poster
2023 ASCO Annual Meeting
Safety analysis by UGT1A1 status of TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI).
First Author: Yohann Loriot
Poster
2023 ASCO Genitourinary Cancers Symposium
TROPHY-U-01 cohort 6: Sacituzumab govitecan (SG), SG plus zimberelimab (ZIM), SG plus ZIM plus domvanalimab (DOM), or carboplatin (CARBO) + gemcitabine (GEM) in cisplatin-ineligible patients (pts) with treatment-naive metastatic urothelial cancer (mUC).
First Author: Ignacio Duran
Poster
2023 ASCO Genitourinary Cancers Symposium
Primary analysis of TROPHY-U-01 cohort 3, a phase 2 study of sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based therapy.
First Author: Petros Grivas